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Summary Introduction This was an open-label, dose escala-
tion (3 + 3 design), Phase I study of SOR-C13 in patients with
advanced tumors of epithelial origin. Primary objectives were
to assess safety/tolerability and pharmacokinetics. Secondary
goals were to assess pharmacodynamics and efficacy of SOR-
C13.Methods SOR-C13 was administered IV QD on days 1–3
and 8–10 of a 21-day cycle. Doses were 2.75 and 5.5 mg/kg
(20-min infusion) and 1.375, 2.75, 4.13 and 6.2 mg/kg (90-min
infusion). Toxicity was assessed by National Cancer Institute
(NCI) Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0. Dose limiting toxicity (DLT) was
assessed within the first treatment cycle. Tumors were evaluat-
ed, using Response Evaluation Criteria in Solid Tumors
(RECIST) 1.1, after two cycles. Results Twenty-three patients
were treated. No drug-related serious adverse events occurred.
DLTs occurred in six patients: asymptomatic, drug-related,
transient Grade 2 hypocalcemia (4 patients), and unrelated
Grade 3 anemia and Grade 3 atrial fibrillation, 1 patient each.
Calcium and vitamin D supplementation eliminated further
Grade 2 hypocalcemia. One Grade 3 treatment emergent
adverse event, urticaria, was definitely related to SOR-C13.
Four possibly drug-related, Grade 3 events (alanine amino-
transferase and aspartate aminotransferase elevation, headache,
and hypokalemia) were observed. Of 22 evaluable patients,
54.5% showed stable disease ranging from 2.8 to 12.5 months.
The best response was a 27% reduction in a pancreatic tumor
with a 55% reduction in CA19–9 levels at 6.2 mg/kg.
Conclusion SOR-C13 was safe and tolerated up to 6.2 mg/kg.
The Maximal Tolerated Dose (MTD) was not established.
Stable disease suggested antitumor activity.
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Introduction
SOR-C13 is a short segment (13-mer) from the C-terminus of a
paralytic peptide soricidin (accession number P0C2P6) discov-
ered in the saliva of the Northern Short-tailed shrew (Blarina
brevicauda), abundant in eastern North America. While not
paralytic themselves, C-series peptides blocked calcium uptake
by ovarian cancer cells in in vitro studies. Eventually the cal-
cium blocking activity of SOR-C13 was traced to inhibition
(IC50 = 14 nM) of member six of the Transient Receptor
Potential Vanilloid family of calcium channels (TRPV6) [1].
TRPV6 is predominantly found in non-excitable tissues with
its main presence in the intestinal tract where it is responsible
for capturing calcium at the apical membrane of enterocytes to
begin the process of trans-cellular shuttling into the body.
While the greatest levels of TRPV6 are in the gut, it has been
variably reported in kidney, pancreas, prostate, salivary gland,
placenta, and breast. TRPV6 is constitutively active and about
100-fold more selective for calcium over monovalent cations.
Early in the study of TRPV6 (then called CaT1 or EaCa1)
experiments showed the channel was significantly over
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expressed in a several cancers compared to corresponding
healthy tissues. Colon cancer (SW480) and myelogenous leu-
kemia (K-562) cell lines were the first cancer cells noted to
express TRPV6 mRNA [2]. In prostate cancer the expression
of TRPV6 was positively correlated to the Gleason score [3,
4], tumor grade [5] and extra-prostatic growth [6] to a degree
that these authors, in the early 2000s, recognized the potential
of TRPV6 in diagnosis and prognosis of prostate cancer, and
as a target for therapy. Suggestions of a role for TRPV6 in
cancers expanded with recognition of the channel in a number
of different malignancies including breast, ovary, colon, thy-
roid and pancreas [7]. This calcium channel has been impli-
cated in breast cancer where its mRNA expression is up to 15-
fold greater in biopsy material than healthy tissue [8] and
correlates positively with poor prognosis in estrogen receptor
negative tumors [9]. Further, TRPV6 protein is elevated in
invasive tissues in 93% of 15 breast cancer biopsies [10] such
that the channel was again identified as a possible therapeutic
target in breast cancer [11]. In-house studies of ovarian cancer
biopsies indicate that TRPV6 mRNA and protein are elevated
across all stages and grades of five types of this disease.
Elevated TRPV6 and the resulting sustained elevation of
intracellular calcium acts through downstream activation of
Nuclear Factor of Activated T-cell signalling system (NFAT;
a transcription factor) in prostate cancer [12]. Also, NFAT
signalling is necessary for survival and metastasis of cells in
breast cancers [13]. Reduction of TRPV6 expression by si-
lencing RNA results in decreased cell proliferation and in-
creased apoptosis in prostate [12] and breast cancer cell lines
[8]. In prostate cancer at least, increased trafficking of TRPV6
to the cell membrane with increased calcium influx increases
cell proliferation, metastasis and inhibition of apoptosis, and
was suggested as a survival mechanism deployed by three
prostate cancer cell lines [14]. The role of TRPV6 in cancer
has been recently reviewed [15, 16].
The recent publication of the first 3D structure of the com-
plex, tetrameric TRPV6 channel [17] should accelerate dis-
covery of therapeutic molecular interventions to exploit it as
an anticancer target. Until that time SOR-C13 remains the
first-in-class, high affinity and selective antagonist of
TRPV6 to enter human trials as an anti-cancer agent.
SOR-C13 was effective in inhibition of tumors in xenograft
models of ovarian and breast cancer. Studies with fluorescently
tagged SOR-C13 showed rapid uptake by ovarian xenograft
tumors with signals becoming well visible in about 20–
30 min, maximizing at about 1 h and maintaining for at least
72 h [1]. Similarly, super-paramagnetic iron oxide nanoparticles
(SPIO) to which a related TRPV6-binding peptide was attached
allowed facile imaging of ovarian xenograft tumors byMRI [1].
In rat and dog GLP toxicology studies, where SOR-C13
was injected as a daily IV bolus for 28 days, there was mini-
mal toxicity and no antigenicity. Importantly there was no
cardiovascular toxicity in either species as expected due to
the absence of TRPV6 in cardiac tissue [18]. The lack of
cardiotoxicity was further substantiated by studies of hERG
and voltage-gated calcium, sodium and potassium channels
where there was no modulation of channel activity by SOR-
C13. Anatomical pathology provided a No Observable
Adverse Effect Level (NOAEL) of 200 mg/kg/day for rats.
For beagle dogs, anatomical pathological study showed the
NOAEL to be 20 mg/kg. There was a short half-life in the
blood compartment (<5 min) in mice, rat and dog but peptide
degradation half-lives in rat and human plasma were about 1 h
indicating that there would be minimal drug degradation be-
fore clearance from plasma. With results indicating antitumor
activity in animal studies, a small toxicological footprint, a
novel oncology target and a mechanism of action supported
by the literature, SOR-C13 was formulated for intravenous
injection (IV) for clinical evaluation. Here we present results
of the ‘first-in-human’, Phase I clinical study evaluating SOR-
C13 in adults with advanced solid tumors of epithelial origin
refractory to all standard-of-care treatments.
Methods
Patient selection
Patients were eligible for the study if they were at least
18 years old and had a histologic diagnosis of a solid
tumor of epithelial origin that failed to respond to previ-
ous standard treatments. An Eastern Cooperative
Oncology Group Performance (ECOG) score of 0 or 1,
and life expectancy greater than 12 weeks were required.
Candidates had to have recovered from major infections
or surgical procedures and, in the opinion of the clinical
investigator, had no other significant concurrent medical
illnesses preventing their participation in the study.
Prospective candidates were required to have adequate
organ and marrow function as defined as: hemoglobin
(≥5.6 mmol/L); white blood cells (WBC) ≥3 × 109/L;
absolute neutrophil count ≥1.5 × 109/L; platelets
≥100 × 109/L; total bilirubin ≤1.5 x Upper Limit of
Normal (ULN); aspartate aminotransferase (AST)/alanine
aminotransferase (ALT)/ alkaline phosphatase (AP) ≤2.5 x
ULN (ALT/AST ≤ 5.0 x ULN in case of documented liver
metastases); creatinine ≤1.5 x ULN; albumin ≥30 g/L;
International Normalized Ratio (INR) ≤1.4.
Trial candidates had to have the ability to understand and
voluntarily sign the informed consent document. Once
deemed eligible for the study and baseline evaluations were
completed, patients were scheduled to receive two cycles of
SOR-C13 treatment. In addition to the treatment visits on
Days 1–3 and 8–10 of the cycle, patients also attended the




This was an open-label, Phase I, dose-escalation study. The
study (ClinicalTrials.gov Identifier NCT01578564) was
conducted at two sites in Canada and one site in the United
States of America and was approved by institutional review
boards at each study site. All aspects of the study were
conducted in accordance with the Declaration of Helsinki
and the International Conference of Harmonisation and
Good Clinical Practice (ICH/GCP) guidelines.
Dose-escalation was carried out according to a standard
3 + 3 design [19]. At each dose level, cohorts of 3 to 6
patients were scheduled to receive two 21-day cycles of
SOR-C13 treatment. SOR-C13 was administered on days
1–3 and 8–10 of the 21-day cycle was administered by IV
infusion. The study drug (500 mg/vial) was dissolved in
water for injection (2 mL) and diluted in saline prior to
infusion to provide a 250 mL (total) infusion volume.
Infusion time was increased after the first five patients
from the initial 20 min to 90 min with the aim of increas-
ing the safety and tolerability of the drug. In the event of
clinically meaningful response (tumor response or stable
disease), additional SOR-C13 cycles were offered to study
patients. Post-treatment follow-up was completed one and
two months after completion of SOR-C13 treatment.
Safety assessments
A Safety Monitoring Committee (SMC) oversaw the
safety aspects of the study. Safety endpoints included:
incidence of adverse events (AEs) and serious AEs
(SAEs), withdrawals due to AEs, Dose Limiting
Toxicities (DLTs), infusion reactions, deaths on study,
vital signs, electrocardiogram (ECGs), clinical laboratory
parameters and changes to the treatment regimen (dose
delay, dose decrease) due to AEs. The National Cancer
Institute (NCI) Common Terminology Criteria for
Adverse Events (CTCAE) Version 4.0 was used to grade
the severity of AEs.
Definition of dose limiting toxicities (DLT)
DLT was initially defined as a single event of ≥Grade 3 tox-
icity or a single event of Grade 2 toxicity or higher over the
first 21-day cycle of SOR-C13 treatment considered possibly,
probably or definitely related to the study drug. Based on the
safety data from the first two cohorts, the regulatory authori-
ties approved a revision of the definition to Bone occurrence of
≥Grade 3 toxicity or one occurrence of Grade 2 hypocalcemia,
over the first 21-day cycle^. The latter definition was used for
the subsequent four cohorts in the study.
Anti-tumor activity
Anti-tumor activity was evaluated by radiologic assessment of
tumor size according to the New Response Evaluation Criteria
in Solid Tumors (RECIST), Revised Guideline Version 1.1 [20]
and changes in tumor-specific biomarker levels. The baseline
radiologic assessment was performed ≤30 days prior to the first
SOR-C13 dose. Tumor response was assessed after two cycles
of treatment (between Days 15–21 of Cycle 2). For patients
receiving additional cycles, tumor response was assessed after
every 2 additional cycles, or earlier at the investigator’s discre-
tion or as required by standard of care at the site.
Pharmacokinetics and pharmacodynamics
Blood samples were taken onDays 1, 3, 8 and 10 of Cycle 1 to
assess the pharmacokinetic (PK) profile of SOR-C13 at the
various doses used. Plasma samples for the IV 20min infusion
were taken at pre-infusion, 5, 15 min after the start of infusion
and post-infusion at 2, 5, 10 and 30 min and 1, 4 h. Plasma
samples for SOR-C13 analysis for the 90 min infusion were
taken pre-infusion, at 5, 15 and 45 min after the start of infu-
sion, and at 2, 5, 10 and 30 min post-infusion. Since the infu-
sion for the majority of patients, and further studies will be IV
90 min only PK data for this infusion time are presented.
Validated liquid chromatography-mass spectrometry analysis
provided the plasma concentration/time data.
For pharmacodynamic information changes of the plasma
biomarkers ‘cleaved cytokeratin 18’, (ccK18) and TRPV6
mRNA levels, in response to treatment, were evaluated.
Blood samples for the assessment of ccK18, TRPV6 mRNA
or other tumor-specific biomarkers were collected within 24 h
prior to the first infusion of SOR-C13, on Day 1 of Cycle 2,
once between Days 15–21 of Cycle 2, during additional cy-
cles, and at the Month 1 follow-up.We set a low basal level of
ccK18 as 250 U/L as a cut-off point representing the 95th
percentile median of healthy volunteers (Peviva M30
Apoptosense ELISA assay product literature).
Statistical analysis
This was a traditional Phase I B3 + 3^ trial designed to detect
clinically relevant adverse experiences which may occur with
a frequency of 33% [19]. No inferential statistics and no for-
mal sample size estimations were performed.
Results and discussion
Patient population and disposition
Twenty-three patients with advanced solid tumors were en-
rolled and received at least one dose of SOR-C13 in one of
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six dose cohorts. Characteristics of the patient population are
given in Table 1. The study enrolled patients with various
solid tumors including: ovarian and colorectal cancer (4 pa-
tients, 17.4% each), Non- small cell lung (3 patients, 13.0%),
and pancreatic cancer (2 patients, 8.7%). Other cancer types,
one patient each, were breast, uterine, prostate, esophageal,
neck, parotid, nasopharyngeal, gastrointestinal stromal carci-
noma, peritoneal cancer, and carcinoma of the base of the
tongue. Mean cancer duration from diagnosis in the overall
population was 47.3 months (range, 8.9 to 115.8 months). All
patients had received prior cancer treatments. Overall, the
mean age of the study population was 58.6 years (range, 29
to 78 years) with a majority being females (16 of the 23 pa-
tients, 69.6%) and Caucasian (18 patients, 78.3%).
Of the 23 treated patients, 22 completed at least one cycle
of treatment, and 20 completed at least two cycles of treat-
ment; one patient was withdrawn after two infusions due to
non-compliance and two patients were withdrawn due to dis-
ease progression (PD) after nine and six infusions, respective-
ly. Efficacy evaluation was performed on 22 patients and 21
completed 2 cycles of treatment (one tumor assessment was
done before two cycles were complete).
The occurrence of DLTs (namely short-lived Grade 2 reduc-
tions in serum calcium) led to dose de-escalation from the initial
5.5 mg/kg to 2.75 mg/kg and subsequently to an increase in the
infusion duration from 20 to 90 min. A further decrease in dose
to 1.375 mg/kg occurred due to the occurrence of a DLT (short-
lived Grade 2 ionized calcium) at the 2.75 mg/kg dose given
over 90 min. However, after demonstration of the safety and
tolerability of the 1.375 mg/kg, 90-min regimen, approval was
given for resumption dose escalation to 6.2 mg/kg with manda-
tory calcium (1000 mg) and vitamin D (1000 IU) supplementa-
tion. The dose cohorts are shown in Table 2.
A total of 486 infusions (including one partial) were adminis-
tered at the following dose levels and infusion durations: 5.5 mg/
kg, 20 min (30 infusions plus one partial infusion), 2.75 mg/kg,
20 min (55 infusions), 1.375 mg/kg, 90 min (93 infusions),
2.065 mg/kg, 90 min (9 infusions), 2.75 mg/kg, 90 min (95
infusions), 3.10 mg/kg, 90 min (49 infusions), 4.13 mg/kg,
90 min (92 infusions), 6.20 mg/kg, 90 min (62 infusions).
Safety and tolerability
Dose limiting toxicities
DLTs occurred in six patients (26.1%), two each in Cohorts 1
(5.5 mg-kg, 20min) and 6 (6.20 mg/kg, 90 min), and one each
in Cohorts 2 (2.75 mg/kg, 20 min) and 4 (2.75 mg/kg,
90 min); refer to Table 3. In the first four cases (two cases in
Cohort 1; one in Cohort 2; and one in Cohort 4), the DLTwas
Grade 2, treatment-related reduction in serum calcium levels
or ionized calcium of short-term duration. In each case, the
patients remained asymptomatic and the laboratory abnormal-
ity resolved within 4 to <24 h after detection. After mandatory
oral calcium and vitamin D supplementation was introduced
for Cohort 4, no further DLTs due to reduced serum calcium
levels were observed. The final DLTs, both in Cohort 6, were
Grade 3 anemia and Grade 3 atrial fibrillation both assessed as
unrelated to the study drug.
Each of the four serum calcium DLT events resulted in mod-
ifications in subsequent dosing, as required by the study proto-
col. Patients in Cohort 1 initially received SOR-C13 at 5.5mg/kg
as 20-min IV infusions. The occurrence of DLT (Grade 2 low
serum calcium) in the next two patients in Cohort 1 led to ces-
sation of recruitment into this cohort and a dose-reduction to
2.75 mg/kg for the affected patients. Cohort 2 enrolled patients
at the de-escalated dose of 2.75 mg/kg administered as 20-min
IV infusions. After the occurrence of a DLT in this Cohort, the
duration of the study drug infusions was extended from 20 to
90 min without a dose-reduction, at the recommendation of the
Table 1 Characteristics of the
patient population Characteristic Overall (N = 23)
n (%)
Median Age, years (range) 58.6 (29–78)
Gender Female/Male 16/7 (69.6%)/(30.4%)
ECOG Performance Status 0 8 (34.8%)
1 15 (65.2%)
Number of prior anticancer therapies 0–1 0
>1 23 (100%)
Cancer types Ovarian, 4; colon, 4; NSCLC, 3; pancreatic, 2; 1 each of breast,
peritoneal, esophageal, uterine, GI stromal, prostate, parotid, head and neck,
nasopharyngeal, adenoid cystic,
Table 2 Listing of cohorts and SOR-C13 dose for each cohort








study SMC. The occurrence of one Grade 2 low ionized calcium
(second DLT in Cohort 2) necessitated a further de-escalation of
dose to 1.375mg/kg, administered as a 90-min infusion. Patients
in Cohort 6 initially received 6.2 mg/kg as 90-min IV infusions.
After experiencing a DLT, (Grade 3 anemia and Grade 3 atrial
fibrillation) two patients received subsequent infusions at a re-
duced dose of 3.10mg/kg even though the events were unrelated
to the study drug. The study protocol required a 50% dose re-
duction for each first occurrence (and discontinuation after recur-
rence) of any Grade 3 AEs, irrespective of causality.
Treatment-emergent adverse events
All 23 patients experienced one or more TEAEs for a total of
185 events. The most common TEAEs in patients receiving
SOR-C13 by Medical Dictionary for Regulatory Activities
System (MedDRA) Organ Class (SOC) were: Metabolism and
nutrition disorders (65%), Gastrointestinal disorders (48%),
Infections and infestations (48%), Investigations (44%), and
General disorders and administration site conditions (44%). A
summary of TEAEs as assessed by Medical Dictionary for
Regulatory Activities (MedDRA) Preferred Term (PT) is given
in Table 4. The most common TEAEs (>20%) were as follows:
fatigue (30%), hypoalbuminemia (30%), anemia (30%), urinary
tract infection (30%), blood calcium decreased (22%), de-
creased appetite (22%), nausea (22%).
Treatment-emergent adverse events (TEAE) related
to the study drug
Sixteen patients (70% of the total population) experienced a
total of 41 TEAEs assessed by the investigator related to the
study drug as follows: Possibly related TEAEs (15 patients, 29
events), probably related TEAEs (4 patients, 7 events) and
definitely related TEAEs (2 patients, 5 events). The common
(> 10%) drug-related TEAEs by MedDRA PT (Table 5),
were: hypoalbuminemia (7 patients [30%], 10 events), re-
duced serum calcium, coded as blood calcium decrease (3
patients [13%], 8 events), and hypocalcemia (3 patients
[13%], 3 events). Note that serum albumin levels were not
evaluated in the first two Cohorts and thus it was possible that
the occurrence of hypoalbuminaemia may be underreported if
these data for these patients were available. In addition, in-
creased aspartate aminotransferase (AST) and decreased ap-
petite were reported for 2 patients each (9%). The remaining
possibly drug-related TEAEs occurred in one patient each
namely, abdominal distension, alanine aminotransferase
(ALT) increased, anemia, blood lactate dehydrogenase
(LDH) increased, constipation, dysphonia, headache, hyper-
sensitivity, hypokalemia, nausea, maculopapular rash, urticar-
ia, and vomiting.
Amongst the 18 patients who received 90-min infusions of
SOR-C13, the frequency of drug-related TEAEs increased
with increasing dose: 0% in Cohort 3 (1.375 mg/kg), 67% in
Table 3 Listing of Dose Limiting Toxicities (DLTs), by cohort and relationship to the drug
Cohort TEAE MedDRA PT Study cycle day Dose# Dose level Severity Relationship
1 Blood calcium decreased C1 D8 4 5.50 mg/kg Grade 2 Definitely related
Blood calcium decreased C1 D2 2 5.50 mg/kg Grade 2 Probably related
2 Blood calcium decreased C1 D2 2 2.75 mg/kg Grade 2 Probably related
4 Ionized calcium decreased C1 D3 3 2.75 mg/kg Grade 2 Possibly related
6 Anaemia C1 D18 Post 6 6.20 mg/kg Grade 3 Unrelated
Atrial fibrillation C1 D8 Post 3 6.20 mg/kg Grade 3 Unrelated
DLTwas defined for Cohort 1 and 2 as a single event of ≥Grade 3 toxicity or a single event of Grade 2 toxicity or higher over the first 21-day cycle of
treatment considered possibly, probably or definitely related to the study drug.; for Cohort 4 and 6: one occurrence of ≥ Grade 3 toxicity or one
occurrence of Grade 2 hypocalcemia over the first 21-day cycle
C cycle, D day of cycle, MedDRA Medical Dictionary for Regulatory Activities, PT preferred term, TEAE treatment-emergent adverse event
Table 4 Common (>10% of population) treatment emergent adverse
events by MedDRA preferred term criteria
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TEAE Treatment Emergent Adverse Event
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Cohort 4 (2.75 mg/kg), and 100% in Cohort 5 (4.13 mg/kg),
and Cohort 6 (6.20 mg/kg) (Table 5). The most common study
drug-related TEAEs in patients receiving SOR-C13 as 90-min
infusions (n = 18), byMedDRA PT, were: hypoalbuminaemia
(7 patients [30%], 10 events), reduced serum calcium, coded
as hypocalcemia (3 patients [13%], 3 events) and calcium
ionized decreased (1 patient [4%], 1 event), followed by
AST increased, and decreased appetite (2 patients [9%], 3
events each). In addition, the following study drug-related
TEAEs occurred in one patient each: abdominal distension,
ALT increased, anaemia, blood LDH increased, headache,
hypokalemia, nausea, maculopapular rash, and vomiting.
No Grade 4 TEAE occurred during the study. Thirteen pa-
tients experienced a total of 18Grade 3 TEAEs. Anemiawas the
only Grade 3 TEAE reflecting clinically significant hematolog-
ical abnormalities (occurring in 2 patients, 1 event each, at doses
of 2.75mg/kg and 6.20mg/kg, 90min infusions) and all but one
was assessed to result from a combination of the underlying
cancer and the intensive blood draw schedule in the study.
Five of the 18 Grade 3 TEAEs were assessed as related to the
study drug: urticaria (Cohort 1), ALT increased and AST in-
creased (Cohort 4), headache (Cohort 4), and hypokalaemia
(Cohort 5). The one instance of urticaria occurred in one patient
in Cohort 1 (5.5 mg/kg, 20-min infusion) but once mandatory
pre-treatment with anti-histamine was implemented, no similar
reactions occurred. There was one withdrawal (in Cohort 4 after
four cycles) due to Grade 3 TEAEs of increased ALT and AST
which persisted for >21 days, and assessed as possibly related to
the study drug. It should be noted that these Grade 3 increased
ALTand ASTwere not cited as DLTs because the definition for
DLT in these cohorts required the event to be within the first 21-
day cycle of treatment.
No drug-related Serious Adverse Events (SAEs) occurred
during the study.
A total of six SAEs were reported for five patients; of these,
five SAEs occurred during the study: Grade 2 rectal haemor-
rhage (Cohort 4), two SAEs of Grade 3 pneumonia (Cohort 6),
one event each of Grade 3 pleural effusion and Grade 3 atrial
fibrillation (both in Cohort 6); see narratives in the Main
Clinical Study Report (18 May 2016). The sixth SAE (deep
vein thrombosis, Cohort 5) was a post-study event. None of
the SAEs were assessed by the investigator as study drug-
related. No deaths occurred during treatment or the protocol-
specified post-treatment follow-up period (i.e., within two
months after the last study drug administration).
Haematology
Anemia was the only TEAE reflecting a clinically significant
hematological abnormality reported, and was deemed primar-
ily related to the intense blood draw schedule in the study in all
but one case. Grade I anemia was observed in two patients,
and Grade 2 anemia in four patients, all assessed as unrelated
to the study drug. There were two events of Grade 3 anemia:
one at the dose of 4.2 mg/kg was assessed as possibly related
to the study drug; the second at the dose of 6.25 mg/kg
assessed as unrelated to the study drug.
Blood chemistry, urinalysis and vital signs
Apart from the reductions in serum calcium and albumin, and
events of ALT and AST increased and hypokalemia described
above, there were no clinically significant alternations in
blood chemistry or urinalysis related to the study drug.
There were no clinically significant changes in diastolic or
systolic blood pressure, pulse, temperature or respiration rate.
There was a slight trend towards reduced blood pressure dur-
ing and immediately post-infusion that normalized by the end
of the post-infusion follow-up.
Effects on the ECG
No clinically significant ECG abnormalities were detected
during the study. There were no clinically significant or
Table 5 Treatment emergent adverse events related to the study drug




















Patient Event Patient Event Patient Event Patient Event Patient Event Patient Event Patient Event
Any TEAEs 3 (100) 49 2 (100) 11 3 (100) 25 6 (100) 52 3 (100) 14 6 (100) 34 23(100) 185
Definitely related 2 (67) 5 0 (0) 0 0 (0) 0 0 (0) 0 0 (0) 0 0 (0) 0 2 (9) 5
Probably related 2 (67) 3 1 (50) 1 0 (0) 0 0 (0) 0 1 (33) 3 0 (0) 0 4 (17) 7
Possibly related 2 (67) 3 0 (0) 0 0 (0) 0 4 (67) 11 3 (100) 5 6 (100) 10 15 (65) 29
Remotely/Unlikely related 1 (33) 4 0 (0) 0 1 (33) 2 2 (33) 4 0 (0) 0 0 (0) 0 4 (17) 10
Unrelated 3 (100) 34 2 (100) 10 3 (100) 23 6 (100) 37 2 (67) 6 5 (83) 24 21 (91) 134
TEAE treatment-emergent adverse event
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consistent changes in mean QT or QTc measurements. In pa-
tients receiving SOR-C13 as 90-min infusions (N = 18), dur-
ing Cycle 1, mean changes in QTc intervals ranged from −4.2
to +12.7 msec compared to pre-infusion values. Importantly,
there were no QT or QTc prolongations above 500 msec dur-
ing the study and no patient experienced QTc prolongation
>60 msec compared to baseline or same-day pre-dose values.
There was an instance of atrial fibrillation in an elderly female
patient in Cohort 6 that qualified as a DLT, however the event
was assessed as not related to the study drug.
Pharmacokinetic evaluation
Since further development of this drug will likely rely on an
infusion time longer than the 20 min used early in this study,
only PK data for the 90 min infusion is presented. SOR-C13
was detected in plasma at 5 min after the start of infusion and
continued to rise during the infusion. There were no marked
differences in plasma SOR-C13 levels between 15 and 45 min
after the start of infusion, suggesting steady state was achieved
by 15 min post-infusion. Plasma SOR-C13 levels generally
Table 6 Pharmacokinetic parameters for SOR-C13 administered as a 90-min infusion
Cohort 3: 1.375 mg/kg; N = 3 Day 1 Day 3 Day 8 Day 10
Peak plasma concentration (ng/mL)
Mean (SD) 243.60 (63.12) 192.83 (96.30) 251.03 (75.53) 224.07 (153.50)
Median 252.50 159.80 237.00 181.00
Min, Max 176.5, 301.8 117.4, 301.3 183.5, 332.6 96.7, 394.5
Time to peak plasma concentration (hr)
Mean (SD) 0.527 (0.387) 0.193 (0.098) 0.787 (0.726) 0.583 (0.289)
Median 0.750 0.250 0.750 0.750)
Min, Max 0.08, 0.75 0.08, 0.25 0.08, 1.53 0.25, 0.75
AUCtau (ng.hr./mL)
Mean (SD) 255.83 (83.25) 148.30 (35.88) 220.33 (35.68) 183.73 (60.12)
Median 263.30 167.50 230.40 215.40
Min, Max 169.1, 335.1 106.9, 170.5 180.7, 249.9 114.4, 221.4
Cohort 4: 2.75 mg/kg; N = 6 Day 1 Day 3 Day 8 Day 10
Peak plasma concentration (ng/mL)
Mean (SD) 523.53 (652.28) 373.74 (397.07) 239.20 (121.86) 289.60 (197.84)
Median 193.65 265.10 281.70 231.80
Min, Max 72.1, 1755.9 10.8, 1052.9 25.1, 344.8 138.0, 681.9
Time to peak plasma concentration (hr)
Mean (SD) 0.665 (0.556) 0.672 (0.565) 0.360 (0.312) 0.610 (0.551)
Median 0.750 0.750 0.250 0.500
Min, Max 0.08, 1.58 0.08, 1.53 0.08, 0.75 0.08, 1.58
AUCtau (ng.hr./mL)
Mean (SD) 435.18 (545.34) 364.70 (369.28) 214.98 (140.77) 273.80 (233.95)
Median 102.75 250.20 246.70 191.75
Min, Max 55.5, 1241.8 10.9, 990.2 13.8, 399.8 76.7, 714.8
Cohort 5: 4.13 mg/kg; N = 3 Day 1 Day 3 Day 8 Day 10
Peak plasma concentration (ng/mL)
Mean (SD) 139.27 (182.68) 369.20 (114.55) 211.57 (131.31) 280.13 (115.58)
Median 42.00 403.20 263.70 295.10
Min, Max 25.8, 350.0 241.5, 462.9 62.2, 308.8 157.8, 387.5
Time to peak plasma concentration (hr)
Mean (SD) 0.417 (0.289) 0.583 (0.289) 0.303 (0.387) 0.360 (0.348)
Median 0.250 0.750 0.080 0.250
Min, Max 0.25, 0.75 0.25, 0.75 0.08, 0.75 0.08, 0.75
AUCtau (ng.hr./mL)
Mean (SD) 78.37 (102.65) 373.00 (112.04) 197.23 (145.72) 273.10 (160.95)
Median 23.40 403.40 245.10 324.20
Min, Max 14.9, 196.8 248.9, 466.7 33.6, 313.0 92.8, 402.3
Cohort 6: 6.2 mg/kg; N = 6 Day 1 Day 3 Day 8 Day 10
Peak plasma concentration (ng/mL)
Mean (SD) 1149.97 (1363.26) 1015.62 (946.49) 1441.90 (1331.10) 1384.57 (1399.83)
Median 681.95 842.60 826.45 793.60
Min, Max 287.0, 3910.1 128.6, 2786.3 334.2, 3556.6 474.2, 4130.6
Time to peak plasma concentration (hr)
Mean (SD) 0.943 (0.530) 0.462 (0.584) 0.763 (0.672) 0.602 (0.534)
Median 0750 0.165 0.750 0.500
Min, Max 0.25, 1.58 0.08, 1.53 0.08, 2.00 0.08, 1.53
AUCtau (ng.hr./mL)
Mean (SD) 1134.65 (1561.93) 1099.75 (1065.70) 1340.23 (1134.54) 1426.38 (1501.23)
Median 570.10 904.50 843.40 830.30
Min, Max 111.1, 4264.6 73.2, 3120.2 437.1, 3223.4 491.6, 4426.8
AUCtau Area Under the Curve for the dosing interval
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increased with increasing dose, the only exception to this being
the data for 4.13 mg/kg were mean plasma levels were at times
lower than those for the 2.75 mg/kg dose. This appeared to be
due to large variability in two patients on some dosing days.
SOR-C13 plasma levels declined rapidly once the infusion
was stopped. For the lowest dose of 1.375 mg/kg, plasma
SOR-C13 was undetectable after 10 min post-infusion. For
the 2.75 and 6.2 mg/kg doses, plasma levels were detectable
10min post-infusion, but in the majority of cases not at 30min
post-infusion (with the exception of one patient).
Assessment of peak plasma concentration (Cmax) and Area
Under the Curve for the dosing interval (AUCtau) confirmed
increasing plasma concentration and total exposure with in-
creasing SOR-C13 dose (Table 6). Mean (± SD) Cmax ranged
from 192.83 ± 96.30 ng/mL for the 1.375 mg/kg dose to
1149.97 ± 1363.26 ng/mL for the 6.2 mg/kg dose. The
AUCtau ranged from 148.30 ± 35.88 ng.hr./mL to
1426.38 ± 1501.23 ng.hr./mL. There was no evidence of accu-
mulation or enhanced clearance of SOR-C13 upon repeated
dosing (Fig. 1a, b). Due to the rapid clearance of SOR-C13 once
infusion was stopped, values for the elimination half-life (Thalf)
and the elimination rate constant could not be calculated in the
majority of cases. Overall, the estimated Thalf was <5 min. .
Pharmacodynamic evaluation
Pharmacodynamic assessments measured the plasma levels of
ccK18, a caspase-cleaved cytokeratin produced during apopto-
sis, and circulating TRPV6 mRNA presumably from cancer
exosome production. The latter was not technically possible
because of large variability produced by mRNA isolation pro-
tocols. The former, while a measure of the general level of
apoptosis, did not increase as expected during the treatment
course and was highly variable. On the other hand, it was clear
that lower basal levels of circulating ccK18 correlated with a
positive response to the study drug in terms of stable disease
after two treatment cycles. Of those patients that showed stable
disease 73% had ccK18 < 250 U/L while 86% of patients who
showed progressive disease had ccK18 > 250 U/L (Fig. 2).
This trend may reflect basal tumor load and, with such low
numbers is not predictive, but it suggests closer monitoring as
development of this drug continues. A similar correlation be-
tween lower ccK18 values and stable disease and between
elevated ccK18 and progressive disease has been previously
observed in patients with gastrointestinal adenocarcinoma [21].
Antitumor activity
The data suggest that SOR-C13 has anticancer activity with
stable disease being observed in 12 of the 22 evaluable pa-
tients (54.5%) after two cycles of SOR-C13 in a wide variety
of tumor types. It was not possible to assess dose response
relationships because of the small number of patients and a
large variety of tumor types. However, stable disease was
observed at the lowest dose evaluated 1.375 mg/kg, given as
a 90-min infusion, as two out of the three patients treated at
this dose displayed stable disease after two cycles. Figure 3
summarizes the tumor response as percent change in the sum
of diameters from baseline to the monitoring phase after Cycle
2 (Days 15–21), as well as which patient showed stable or
progressive disease. Three of the 22 patients were assessed
with progressive disease before completion of target tumor
monitoring, and are not included in Fig. 3.
Encouraging evidence of activity against pancreatic cancer
was observed in both patients with this cancer type. Stable dis-
ease was observed for four cycles in one patient treated at the
2.75 mg/kg dose, and for over 10 cycles in the second patients
treated at the 6.2 mg/kg dose, both as 90-min infusions.
Furthermore, the higher dose produced a 27% reduction from
baseline in the sum of tumor diameters after 4 cycles of treat-
ment approaching the 30% decrease required to qualify as a
partial response. Both patients had failed at least three prior
regimens of anticancer therapy: the patient treated with
2.75 mg/kg received four previous treatment regimes [(i)
IMRT/Tomotherapy plus chemoradiation with FOLFIRINOX,
(ii) carboplatin/gemcitabine/erlotinib (iii) nab-paclitaxel/
gemcitabine, (iv) IMRT/Tomotherapy] while the more respon-
sive patient (with mutations in P53 and KRAS) had undergone
Fig. 1 (a & b) Plasma
concentrations of SOR-C13
during and after 90 min infusions
for (a) four dosing cohorts on
cycle 1 day 1 and (b) cycle 2 day
10. The values are mean ± SEM,
n = 3 to 6
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three previous treatment regimens [(i) FOLFIRINOX; (ii)
gemcitabine and nab-paclitaxel; and, (iii) capecitabine]. Anti-
tumor activity was further supported by reduction in CA 19–9
biomarker levels. In the patient treated at 6.25 mg/kg, a slight
tumor regression detected (− 7%) after cycle 2 was associated
with a 29% decrease in CA 19–9, and the 27% tumor reduction
observed after cycle 4 was associated with a 55% decrease in
CA 19–9. Subsequent tumor progression after a dose reduction
to 3.1 mg/kg due to development of Grade 3 pneumonia was
associated with increases in CA 19–9 levels. In the patient re-
ceiving the lower dose (2.75 mg/kg) for pancreatic cancer, CA
19–9 levels decreased slightly at the end of cycle 1, but returned
to baseline levels at cycle 2 and cycle 4 coincident with stable
disease. Unfortunately, persistent elevation in liver enzymes after
cycle 4 for >21 days necessitated removal of the patient from the
study and further relationship between changes in tumor size and
CA 19–9 levels could not be evaluated.
Prolonged stable disease was also seen in one patient with
adenoid cystic carcinoma of the tonguewho received 18 cycles
(378 days) of SOR-C13 at a dose of 4.13mg/kg. This cancer is
generally indolent so the event should not be over interpreted.
This patient had failed three prior anticancer regimens [(i)
Chemoradiation treatment with cisplatin; (ii) lenalidomide
and temsirolimus; and, (iii) carboplatin and vinorelbine with
pegfilgrastim support. Suggestive activity was also observed
for ovarian cancer (OVca) patients with the observation that
two of the four OVca patients treated displayed stable disease
after 2 cycles of treatment.
Conclusions
SOR-C13 was safe and generally well tolerated in patients with
advanced solid tumors of epithelial origin, without evidence of
the haematological, neurological or other significant toxicities
often observed with cytotoxic chemotherapy. The main adverse
reactions (hypocalcemia, hypersensitivity reactions) identified
as definitely related to the drug can be managed with oral cal-
cium plus vitamin D supplementation, and antihistamine pre-
treatment, respectively. The Maximal Tolerated Dose (MTD)
level for SOR-C13 was not determined in this study and must
be addressed to access efficacy and dose responses in future
development. The study also provided preliminary indications
of anticancer activity for SOR-C13. Promising activity was
seen in both patients with pancreatic ductal adenocarcinoma,
who had failed three prior regimens of anticancer therapy each.
SOR-C13 provides a unique mechanism for anticancer activ-
ity, through inhibition of the TRPV6 calcium channel activity.
Based on good drug tolerability and manageable safety profile,
and coupled with promising anti-tumor activity, further studies
to investigate SOR-C13 as an anti-cancer agent are warranted.
Pancreatic cancer appears to be an appropriate target, given the
high unmet need for this disease. In addition, changes in plasma
Fig. 2 Basal plasma levels of apoptosis biomarker (cleaved cytokeratin-
18: ccK18) ranked with either stable disease (SD, white) or progressive
disease (PD, shaded). A dashed line indicates the ccK18 cut-off value of
250 U/L (upper level of ‘normal’). The patient code number is listed
along with an abbreviation for cancer type. Abbreviations: ACAC:
adenoid cystic adenocarcinoma; PANC: pancreatic adenocarcinoma;
OVAC: ovarian adenocarcinoma; PRAC: Prostate adenocarcinoma;
GIAC: Gastro-intest inal adenocarcinoma; UTAC: Uterine
adenocarcinoma; PAAC: Parotid adenocarcinoma; ESAC: esophageal
adenocarcinoma; COAC: colon adenocarcinoma; NSCL: Non-small cell
lung; NASO: nasopharyngeal Adenocarcinoma; BRAC: Breast
adenocarcinoma; PEAC: Peritoneal adenocarcinoma; LUAC: lung
adenocarcinoma
Fig. 3 Percent change in the sum of diameters of target tumors from
baseline to Cycle 2, Days 15–21. Of the 22 patients evaluated in the
safety section, only 19 (shown here) provided measurements of tumor
size. Three measurements that were smaller than the RECISTcriterion for
stable disease (<20%, dotted horizontal line) showed progressive disease
(shaded bars). Two of these patients (12 and 13) showed a new lesion and
hence classified as progressive disease, while one (8) showed progressive
disease during physical examination. There was no change in tumor
measurements for 15–17. The numbers on the X-axis are arbitrary
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CA 19–9 for evaluating the efficacy of SOR-C13 in pancreatic
cancer, if confirmed, could be useful to inform treatment deci-
sions. The absence of toxicity commonly observed with cyto-
toxic agents provides a rationale for investigation of SOR-C13
with background antineoplastic agents (i.e., combination with
other cancer drugs) to increase anticancer efficacy with reduced
risk of cumulative or overlapping toxicities.
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